NCT02628236View on ClinicalTrials.gov

Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

May 31, 2016

Study Completion Date

July 31, 2016

Conditions
Keratosis, Actinic
Interventions
DRUG

Aminolevulinic Acid (ALA)

20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light

DEVICE

BLU-U

10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2

Trial Locations (2)

77845

J&J Studies, Inc, College Station

78759

DermResearch, Inc., Austin

Sponsors
All Listed Sponsors
lead

DUSA Pharmaceuticals, Inc.

INDUSTRY